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Background: Pharmaceutical drug shortages (DSs) are a global problem which presents challenges to countries
around the world. Shortages of pharmaceutical products may have a direct detrimental impact on public health
and patients’ wellbeing by causing delayed, or even lack of, treatment. Moreover, DSs may force both patients and
caregivers to use unfamiliar drugs, which could lead to medication errors. The objective of our study was to analyze
DSs in Israel during the years 2013–2015, assessing their etiology and exploring the steps taken for their mitigation
and prevention.
Methods: The database of the Israeli Ministry of Health (MoH) on drug shortages contains all the DSs recorded in
Israel since 2013, detailing the cause of the DS, its duration, steps taken in its’ management and the availability of
generic or therapeutic alternatives. Selected examples of DSs from the database are described in this paper in order
to identify the causes of DSs, the scope of the problem and possible solutions. Additionally, we have reviewed the
recent activities performed by European Medicine Agency (EMA) and the American Food and Drug Administration
(FDA) in their efforts to minimize this problem.
Results: Several factors contributing towards DSs in Israel were identified, including quality problems in both the
final drug product and in the raw materials, upgrades and improvements of the manufacturing process required by
the MoH, manufacturing by a sole supplier, dramatic price decrease in off-patent medications causing the
manufacturer to discontinue the distribution of the product in Israel, just-in-time inventory control, and others.
One of the most important steps in managing drug shortages was identified to be early notification of the shortage by
the Marketing Authorization Holder (MAH) to the MoH. In 2013, the Israeli MoH updated the regulation on drug
shortages instructing MAHs on their obligation of early notification to the MoH.
Furthermore, various steps dealing with marketing withdrawal of drugs and temporary drug shortages are being
implemented in Israel, such as suspending any further reductions in drug prices below 17 new Israeli shekels,
instructing all MAHs to maintain no less than 1 month supply of all registered and non-registered drugs in Israel
and allowing an expedited registration pathway for well-established use/grandfather drugs.
Conclusions: Drug shortages pose significant public health hazards worldwide. Early notification to the MoH and open
dialog with MAHs are essential for managing DSs and mitigating their impact. Despite the efforts carried out by health
regulatory authorities worldwide, DSs still pose a significant threat to public health.
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A drug shortage (DS) is defined by the Food and Drug
Administration (FDA) as a situation when: “the total
supply of all clinically interchangeable versions of a
FDA-regulated drug product is inadequate to meet the
current or projected demand at the patient level” [1].
DSs are a global problem relevant to countries regard-
less of size. In the United States (US), the number of
prescription DSs more than tripled between 2005 and
2010, increasing from 61 in 2005 to 178 in 2010 [2].
This significant increase in the number of drugs in
shortage resulted in several actions taken by the US
government in order to address the problem. An execu-
tive order signed by the US President in 2011 and the
FDA Safety and Innovation Act (FDASIA) passed in
2012, both aimed to expand the authority of FDA in
managing DSs and to ensure advanced notification of
anticipated shortages by Marketing Authorization
Holders (MAH) to the FDA. Nevertheless, in spite of
these efforts and their relative success in preventing
DSs, announcements on new shortages appear on the
FDA website almost every week.
As an additional step in coping with the DS challenge
in the US, the FDA recently established the Drug
Shortage Assistance Award program aiming to provide
public recognition to drug companies and manufacturers
who have worked in cooperation with the FDA and have
implemented strategies to help ensure a steady supply of
necessary drugs. Award letters posted on the FDA
website recognize these companies for making a sub-
stantial contribution to preventing or alleviating a DS.
Advocates of this initiative hope that these public letters
will serve as an incentive for other companies to main-
tain a stable drug supply and avoid DSs by working to-
gether with the regulator.
Furthermore, a publicly available database of DSs
was established on an FDA website, keeping all the
stakeholders updated on new entries and resolved
shortages [3].
Data from the European Union (EU) is relatively
lacking compared to the US and most DSs are dealt with
at a national level. Nevertheless, the European Medicine
Agency (EMA) is concerned with DSs as well, focusing
mainly on shortages associated with quality defects
affecting many EU countries. In November 2012, the
EMA published a position paper on medicinal product
supply shortages caused by manufacturing problems [4].
Subsequently, an implementation plan was issued in
order to alleviate the increasing number of unforeseen
DSs at a European Community level [5].
In 2014 the Organization of Economic Co-operation
and Development (OECD) released a report from the
Global Forum on Competition that focused on the
distribution of pharmaceuticals [6]. Shortages in someOECD countries were described. The shortage problem
was not confined to countries with severe financial crises
such as Greece and Spain. The UK, for example, has suf-
fered from systemic shortages and supply disruptions,
mainly due to EU regulations allowing free movement of
medicines within the EU (parallel trade) thereby impact-
ing the balance of individual country supply and de-
mand. UK authorities have responded by introducing
legislation requiring pharmacists to acquire a wholesale
license before they can engage in any parallel trade. They
also established a requirement for the wholesalers, as
their first responsibility, to maintain an appropriate and
continued supply of medicinal products to pharmacies
within UK so that first the needs of local patients are
covered. Breach of this regulation, set by the MHRA,
may lead to regulatory action against the involved
wholesaler, resulting in the revoking of the pharmaceut-
ical license and even criminal prosecution.
The Business and Industry Advisory Committee to the
OECD (BIAC) has suggested that the economic crisis
has forced deep price cuts to pharmaceutical products,
as governments have attempted to reduce healthcare
spending [7]. The causes of DSs, in their view, included
globalization of manufacturing and distribution activ-
ities, leading to fewer supply sites and thus less flexibil-
ity; scale of demand, as well as pricing and
reimbursement policies.
At the beginning of 2016, the World Health
Organization (WHO) released a new report on global drug
shortages [8]. The WHO commented that while DSs are
not a new phenomenon, they have been increasing in
recent years, resulting in increased worldwide concern
regarding the supply of essential medicines.
Shortages of pharmaceuticals can result in delayed
treatment for patients and sometimes even deprivation
of treatment due to lack of availability of the needed
drug. When no appropriate alternative therapy is avail-
able, DSs could lead to a serious threat to public health.
Moreover, DSs are often the cause of medication
errors. Alternative drugs, unfamiliar to clinicians or pa-
tients, different brands or concentrations, altered pre-
sentations, all may cause medication errors, adverse
events and decreased patient adherence.
A recent paper by CL Ventola, emphasized the conse-
quent mortality associated with DSs in the US [9]. For
example, a shortage of a life-supporting oncological drug
could mean a death sentence to patients in need. In a
survey carried out in 2012 in the US among pharmacy
directors from various sectors, including acute care,
non-acute care, management, and industry, 40% of the
participating hospital pharmacies (with more than 85%
of the responders from acute care hospitals) reported
adverse events associated with DSs. DSs were also found
to be associated with numerous medication errors,
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trations. Many responders to the survey reported that
DSs lead to delayed or even cancelled care. These can-
cellations included procedures, surgeries, chemotherapy
and other treatments [10].
Numerous studies and reviews have referred to the
possible impact of DSs on public health. Exploring the
problems and the negative outcomes of DSs, Clauder
et al. have conducted a survey among pharmacy direc-
tors in North Carolina, South Carolina, Georgia, and
Florida [11]. Responders reported that DSs cause 1 to
5% error rates in hospitals, and 60% of the time DSs cre-
ate unsafe conditions for patients and staff. In a survey
carried out in a pediatric Intensive Care Unit (ICU),
surprisingly, no increase in medication error rate was
found due to shortage of sedatives. The authors
hypothesize that the reason for this lack of difference is
ongoing communication and information provided by
the clinical pharmacists and routine face-to-face educa-
tion with prescribers during the shortage period [12].
Besides affecting the quality and the safety of public
health, DSs have a significant financial effect on health
systems. For example, the financial burden of drug sup-
ply disruptions to hospitals in the US was estimated in
2011 to be $200 million annually, because of the need to
purchase more expensive therapeutic substitutes. An-
other $216 million of indirect costs were estimated as a
result of labor costs due to time spent by healthcare
personnel in the management of DSs in hospitals [9, 13].
These estimations take into account only part of the
financial burden of DSs, as they neglect the costs of
incorrect or non-optimal treatment, leading to an in-
creased number of hospitalization days, additional drugs
required, etc. Nearly all responders to a survey carried
out in hospitals and other healthcare institutions in 2010
in the US experienced an increase in drug costs as a
result of a shortage, due to purchasing drugs off-
contract, buying more costly brand names and alterna-
tive medications at increased price due to limited
supplies [14].
In this article, we will describe the current situation in
Israel with reference to other countries emphasizing spe-
cial circumstances relevant to the Israeli health system.
Due to the lack of data on outpatient DSs worldwide,
the analysis of the situation in Israel, and references to
EMA and FDA, focuses mainly on inpatient DSs. Fur-
thermore we will discuss approaches and solutions to
overcome this phenomenon.
Methods
Since 2013, The Israeli Ministry of Health (MoH)
receives and documents notifications regarding supply
shortages from MAH. We have searched this database
to identify the scope of the problem and steps taken bythe Pharmaceutical Division in the prevention and man-
agement of DSs. Furthermore, recent policies by EMA
and FDA in the management of DSs are described.
Results and discussion
Drug shortages in Israel
Based on the data collected by MoH, between 2013 and
2015, 677 DS notifications were received: 191 in 2013,
240 in 2014 and 246 in 2015. In the US, 117, 44 and 44
DSs were tracked in the years 2012, 2013 and 2014, re-
spectively. The FDA helped to prevent 282 DSs in 2012,
170 shortages in 2013 and 101 shortages in 2014 [3]. Of
these DSs, 31% had no available therapeutic alternatives.
Sixty to seventy percent of the DSs were communicated
by MAH to MoH at the time of DS coming into effect
or up to 1 month before, lacking advanced notification
essential for management and prevention of DSs. These
shortages included sole supplier drugs for various
medical conditions, including tranexamic acid tablets
and injection, cefotaxim sodium injection, fluphenazine
decanoate injection, metolazone tablets, ipatropium
bromide respiratory solution, nitroprusside solution,
clomifene citrate tablets, oral midazolam, acyclovir oph-
thalmic ointment, alfacalcidol drops, barium sulfate sus-
pension for radiography, morphine injections, lidocaine
injections, midazolam injections, melphalan injections,
adrenalin injections, etc.
Figure 1 demonstrates the distribution by ATC (Ana-
tomical therapeutic chemical) categories of DSs in Israel
during the years 2013–2015. DSs were disseminated
throughout a wide array of the therapeutic groups and
affected various aspect of medical care. The most
prevalent ones included cardiovascular drugs (15%),
anti-infectives for systemic use (16%) and drugs for the
treatment of nervous system disorders (21%).
The following case studies provide examples of the
complexity of DSs as seen in Israel, some of which may
be relevant to other countries as well.
At the beginning of May 2013, the Israeli MoH re-
ceived a notice of a possible shortage of phenytoin
effective almost immediately and anticipated to last for a
period of up to 6 months. Phenytoin is an anti-epileptic
drug with narrow therapeutic range and non-linear
metabolic elimination. Its therapeutic range is so limited,
that cases of patients developing breakthrough seizures
due to batch-to-batch variations are described in the sci-
entific literature [15]. In dealing with this potential
shortage, a careful assessment and risk minimization
measures are paramount. In a small country like Israel,
where only one drug supplier of phenytoin exists, no
local alternatives are available. Attempts by the MAH to
find another source of drug supply were futile since the
shortage was global. A special task force, including the
four Health Management Organizations (HMOs) and
Fig. 1 Distribution of drug shortage notices by ATC categories in Israel during 2013–2015
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MoH, in order to address this shortage. Due to the nar-
row therapeutic index of phenytoin, it was important to
ensure that the alternative will resemble as much as pos-
sible the currently supplied drug to minimize the risk of
patients developing breakthrough seizures. In collabor-
ation with the Israeli Neurology Association, a decision
was made to supply the remainder of the drug to pa-
tients already receiving phenytoin; directing new patients
towards alternative therapies. Several potential candi-
dates for phenytoin generics were located in Europe.
Since no studies comparing the various phenytoin prod-
ucts were found, it was decided by the task force that
comparative bioavailability tests should be carried out to
determine which of the available alternatives most re-
sembles the product registered and marketed in Israel.
Fortunately, at the last minute, the MAH was able to
find an alternative supply site for the original drug and
the threat of DS was addressed.
Another example of a DS is Clomiphene citrate, a
sole supplier drug used for induction of ovulation.
Following intervention by the MoH, the MAH was
able to allocate to the Israeli market a supply of the
same drug manufactured in Israel for export, thus
temporarily resolving the shortage.
Additional imminent shortage of a topical preparation
for treatment of burn wounds arose following rapid alert
report received by the MoH in 2014 regarding possible
cross-contamination with penicillin. Following risk as-
sessment of drug shortage vs. possible side-effect as a
result of cross-contamination, it was decided to add a
special labeling to the drug’s package notifying the cus-
tomers that this product should not be used in patients
sensitive to beta-lactams. The distribution of the product
was accompanied by a Dear Health Care Provider
(DHCP) letter and a notice to the public made by MoH.In March 2014, a routine inspection of the manufac-
turing facility of oromucosal solution of midazolam, a
drug indicated to stop sudden and prolonged convulsive
seizures in children, was carried out. The inspection
revealed failures in the quality management of the
manufacturing process of the drug, raising concerns re-
garding a potential risk of cross-contamination with
amsacrine, another medicine produced at the same site
used for the induction and maintenance of remission in
acute leukemia in adults. Tests did not find any residuals
of amsacrine. As a precautionary step, the drug was
recalled in Member States where suitable alternative
treatments were available. Due to the lack of available al-
ternatives, the product was classified as critical and it
was decided to maintain its supply to the Israeli market.
One of the major concerns in DSs worldwide is disrup-
tion in the supply of sterile injectables, resulting in severe
impact on public health. During the years 2013–2015 in
Israel, 27% of DSs were supply interruptions of injectables
and approximately 20% of them were IV injections. Sur-
prisingly, this was in contrast to the situation in the US,
where a significantly higher incidence of shortages related
to sterile injectable products was noted. For example,
according to FDA data in years 2011–2012, sterile inject-
ables accounted for about 70% of all DSs [16].
Throughout 2014–2015, Israel experienced three
major DS crises leading to disruption of drug supply;
two of them involved local manufacturing sites. In one
case, all the production of a MAH was moved to a new
manufacturing plant. During the preparation for this
major variation, following discussions between the MoH
and the MAH, it was decided to increase the inventory
of critical drugs to 6 months of use, taking into account
the MAH being the sole supplier for these products.
Unfortunately, due to unexpected production difficulties
at the new facility, these efforts were insufficient, resulting in
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ables such as midazolam, lidocaine and morphine. In an-
other incident, one of the major pharmaceutical companies
in Israel relocated the secondary packaging site of solid oral
dosage form products, creating an ongoing temporary short-
age in 90 of the company’s drugs (some of them with a sin-
gle supplier). Another crisis, related to the transfer of the
production of injectables to a new manufacturing fa-
cility abroad, is still having an impact on their supply
chain, resulting in the need to import non registered
alternatives. The MoH is working closely with the
MAH, other manufacturers, importers and healthcare
institutions to find a solution for this problem.
Etiology of drug shortages in Israel
The etiology of DSs in Israel is similar to FDA and EU,
being multifactorial and related to one or more of the
following factors:
– Quality problems that are not limited to the final
drug product, but often found in the raw materials,
affect drug production and supply around the globe.
Major challenges are quality problems with Active
Pharmaceutical Ingredient (API) from emerging
countries like India and China. Just recently, Good
Manufacture Practice (GMP) approvals of several
large global manufacturers of APIs have been
revoked following inspections carried out by mature
regulatory authorities. Failure of quality
management in facilities that produce the finished
dosage form of the drug was directly responsible for
56% of sterile injectable DSs in 2011 in the US [17].
– Disruption or delay in the supply of the raw or bulk
material can affect multiple manufacturers and result
in a country/regional/worldwide DS. For example, a
shortage of the injectable antibiotic streptomycin was
reported in 15 countries in 2010, with 11 more
countries predicting their stock would run out before
they could be replenished [18].
– Regulatory authorities’ requirements for
improvement of the manufacturing process have
become a complex and expensive effort for
pharmaceutical companies. Many companies,
especially, but not limited to small ones, are unable
or unwilling to make capital investments to
sufficiently upgrade the infrastructure required
according to the updated GMP standards. Hence,
manufacturers often choose to discontinue
production of low priced off-patent drugs. The
phenomena is further accentuated in a small country
with strict regulations like Israel, where local
manufacturers are sometimes required to implement
changes in the manufacturing/validation process of
drugs intended for a relatively small local market.– The situation in Israel, with limited market size and
number of competitors, results in many drugs being
manufactured solely by one company. Therefore, in
case of manufacturing or supply difficulties, the risk for
a nationwide shortage constantly exists. Special
emphasis should be drawn to sterile injectable products
with revenues barely covering the costs of production.
Currently in Israel, numerous old, well established and
extensively used drugs in an ICU setting, like lidocaine,
midazolam and dipyridamole, are manufactured and
registered by a single company.
– Low prices of certain off-patent medicines may
contribute to DSs and drive manufacturers of these
medicines out of the market. Furthermore, in Israel,
reference pricing policy is determined by referencing
overseas countries, but not necessarily reflecting
global and local market conditions. Fluctuations in
currency exchange rates influence prices as well.
This, in turn, may lead to situations in which the
revenue of drugs will not cover the costs of
production, resulting in permanent DSs.
– Just-in-time inventory control by manufacturers,
medical product distributors and healthcare
institutions reduces the possibility to cope with DSs
at times of unexpected demand changes or supply
disruption. In cases in which an MAH is the main
or sole source for a medication on the market, a
manufacturing/supply chain problem can often
result in a DS affecting the entire country.
– The drug market in Israel is centralized and
dominated by Health Management Organizations
(HMOs) with large scale generic medication tenders.
Therefore, all approved generics and innovative drugs
of the same International Nonproprietary Name
(INN) are perceived as switchable by the HMOs (with
the exception of biosimilars, where a different policy
exists). Thus, the HMOs buy their drugs based almost
entirely on pricing. This often leads to a situation,
where an MAH that fails to win a tender discontinues
manufacturing or local distribution of the drug,
resulting in only one alternative with sole supplier on
the market.
– The Israeli regulation currently mandates Certificate
of Pharmaceutical Product (CPP) from a pre-
determined limited set of “authorized countries” as
stated in the legislation. This demand is a prerequisite
for drug registration. Consequently, this limits the
drugs submitted for registration in Israel.
Steps for managing drug shortages based on the Israeli
experience
Unfortunately, without supporting legislation, a regula-
tory authority cannot instruct a pharmaceutical com-
pany/MAH to produce a drug. It also has no capacity to
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between manufacturers and healthcare institutions.
While the root cause of DSs is usually outside the
regulator’s control, some of the shortages can be man-
aged and even prevented by activities promoted by the
MAH and/or the regulator, especially when both parties
collaborate effectively.
One of the key steps in overcoming some of the DSs is
ensuring that the regulator receives a notice of the
upcoming shortage well in advance. Early disclosure of a
shortage by the MAH can allow the regulator to find
alternative solutions to overcome the crisis.
In their attempt to prevent and mitigate DSs, the FDA
implemented section 506 (c) of the Federal Food Drug
and Cosmetic Act requiring MAHs to notify of any
manufacturing discontinuance or interruption in manu-
facturing of the product at least 6 months prior to the
date of the discontinuance or as soon as possible and in
no case later than 5 business days after DS occurs. EMA
requires MAHs to notify the Members State’s competent
authority no less than 2 months before the expected
interruption in the market.
Until May 2013, the Israeli MoH required MAHs to no-
tify only in cases of permanent marketing termination.
The procedure for the notification process in event of
drug shortage, also known as Procedure 104, was updated,
requiring MAHs to notify the MoH of any permanent or
temporary DS anticipated to last more than 2 weeks, at
least 6 months prior to the estimated shortage start date.
This notification requirement enables the Israeli MoH to
monitor DSs in Israel, to receive early notifications of such
incidents and to take risk mitigation measures. Addition-
ally the procedure requires the MAH to discuss any future
termination with the MoH in order to find acceptable
solutions in view of public health considerations. The
MoH reserves the right to instruct the MAH to continue
distribution of a medicine under special circumstances.
During the years 2013, 2014 and 2015, 58, 71 and 64%
(respectively) of the DS notices were received immediately
before the shortage (less than 1 month before the shortage
came into effect). A decrease in immediate notifications
was noted in the months following the update of the pro-
cedure. Nevertheless, in spite of the updated require-
ments, many MAHs still fail to provide the MoH with
adequate notice on forthcoming shortages. The lack of
compliance with the early notification requirements could
be due to the fact that the MAH is not always aware in
advance of future shortages and thus is unable to meet the
requirement for 6 months notification. This is especially
evident when the disruption of the drug supply is caused
by global API shortage, quality issues requiring withdrawal
from the market of one or more batches of the product,
noncompliance with GMP requirements following regula-
tory inspection and others.The Israeli MoH developed a protocol for the man-
agement of DSs based on country specific experience.
According to the protocol, following the MAH notifi-
cation of the forthcoming shortage of drug with no
generic alternatives, the MoH engages all the relevant
stakeholders, including Health Care Professionals
(HCP), HMOs and/or hospitals and drug importers, to
identify a possible solution (e.g. importing similar drug
from abroad or issuing instructions to HCPs regarding
the shortage and the possible therapeutic alternatives).
In some cases, after careful risk evaluation, the MoH
may expedite evaluation of drugs that are in shortage
to allow the distribution of a drug with relatively
minor defects, such as inappropriate labeling or pack-
aging, etc. Cross-contamination of midazolam with
the cytotoxic agent amsacrine, described above in this
manuscript, is an excellent example of risk manage-
ment by the Pharmaceutical Division. In another case,
similarly to the decision taken by the FDA, a product
containing glass particles was allowed to be distrib-
uted into the market accompanied by a filter and a
DHCP letter instructing the HCP to use the filter to
remove potential particles from the product.
According to Procedure 104, it is the responsibility of
MoH to notify the public regarding the forthcoming
shortage. Furthermore, the MoH actively seeks alternative
supply sources of the drug in shortage, to import either a
registered or a non-registered drug. Israeli legislation
allows for importation of non-registered drugs from au-
thorized countries under article 29 C of the Pharmacist
Regulations—Medicinal Products. This allows for a quick
and effective way of obtaining drug supply in shortage.
Another step taken by MoH once a shortage is
imminent is to instruct the MAH to control more ad-
equately the distribution of the drug in shortage, prevent-
ing excess purchase of large quantities by some of the
customers and enabling all the stakeholders to receive ap-
propriate restricted drug quantities. An additional strategy
may be to instruct physicians, to prescribe the remaining
product to defined patient populations and for specific
clinical situations, where no appropriate alternatives are
available, thus switching or initiating the remaining
patients to other therapeutics alternatives.
The presence of a generic drug is not always a
guarantee for preventing DSs. The manufacturer may
not have the flexibility to increase drug production to
meet the national demand in a timely manner, espe-
cially at short notice. The MAH of an imported alter-
native may be unable to increase the supply of the
drug into the country due to lack of finished product,
previous commitments to other customers and deliv-
ery schedules at the manufacturing facility.
In the effort to reduce the number of DSs occurring in
Israel each month, the MoH has recently published
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for authorization of well-established/grandfather drugs.
Such drugs were usually registered in Israel in the past
or are similar to products registered and marketed for
more than 10 years in authorized countries and are
imported to Israel under article 29 C. This procedure is
currently being evaluated for its impact on reducing the
number of non-registered drugs imported to Israel.
One of the causes for cessation of drug distribution in
Israel is price reductions. The pricing reference model in
Israel is based on overseas reference prices of drugs as
well as currency exchange rates. Following the MoH
decision on the reference price, HMOs, using an effect-
ive tender system may reduce the price even further.
This pricing system may be problematic especially with
old drugs and small pharma companies. Reference prices
for old drugs may be so low that any further decrease
makes the production and/or distribution of these im-
portant drugs non feasible. Additionally, small local
pharma companies may find it difficult to cope with
drug suppliers from abroad unwilling to accept the des-
ignated price. This challenge has generated important
discussions within the Ministry on ways to preserve the
availability of such drugs on the market. One of the
strategies chosen to overcome this was to suspend any
further reductions in drugs prices below 17 new Israeli
shekels. The Pharmaceutical Division’s role as an im-
portant stakeholder overseeing DSs was an essential fac-
tor preventing further reductions below this price.
Finally, as part of Israel preparedness to emergency
scenarios (war, earthquake and other natural disasters),
it was decided to instruct all MAHs to hold at any time
at least 1 month’s supply of all registered drugs in Israel.
This strategy was recently published and is monitored
and enforced. This requirement is now applicable to
both registered drugs and new molecules under
evaluation for registration. HMO’s and medical institu-
tions are obliged to ensure a 1 month’s supply of non-
registered drugs which are part of the National Health
Basket and are imported into Israel under article 29 C of
the Pharmacist Regulations—Medicinal Products.
Conclusions
In this paper, we have described the topic of DSs in
Israel, with use of statistics for years 2013–2015. We
have analyzed the etiology of DSs and utilized selected
examples and the actions taken in their management.
Despite all the steps taken by the Israeli MoH to pre-
vent and manage DSs, their number continues to rise
annually. As described in this paper, numerous steps are
being taken in the management of DSs, including early
notification, working closely with the MAH, preservation
of prices for grandfather drugs, procedure 120 and the
request for no less than 1 month drug supply in Israel atany time. In order to prevent the selection of one sup-
plier/brand by HMOs due to generic/generic tenders, it
was even considered to instruct the HMOs to maintain
two suppliers for certain critical drugs, thus limiting the
possibility of sole drug supplier on the market.
The MoH periodically publishes a call for manufac-
tures and importers to apply for registration of old well
established (grandfather) drugs currently imported
under article 29 C. This call was positively taken by
potential MAHs.
The MoH preemptively takes measures to overcome
the challenge of DSs. A designated unit was established
to deal with this ongoing and important task and all DSs
are publicly available on the unit’s website. In spite of
the time and efforts invested, this problem is yet to be
solved. While cooperating with the MAHs is a key factor
for this process, currently, there are no deterring mea-
sures set in legislation, including financial constraints for
any MAH not complying with the requirements set by
the MoH. Introducing these deterring measures could
serve to minimize the frequency of DS.
DSs pose significant public health hazard worldwide.
Early notification and open dialog between the MAH
and the regulator is essential for preventing and mitigat-
ing the impact of shortages. Further collaboration of all
stakeholders, including international stakeholders, is
required to overcome these substantial challenges.
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